Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Jun;68(6):719–725. doi: 10.1136/jnnp.68.6.719

Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)

E Gouzoulis-Mayfran 1, J Daumann 1, F Tuchtenhagen 1, S Pelz 1, S Becker 1, H Kunert 1, B Fimm 1, H Sass 1
PMCID: PMC1736948  PMID: 10811694

Abstract

OBJECTIVES—Ecstasy (3,4-methylenedioxymethamphetamine (MDMA) and related congerers: MDA, MDEA) is the name given to a group of popular recreational drugs. Animal data raise concern about neurotoxic effects of high doses of ecstasy on central serotonergic systems. The threshold dose for neurotoxicity in humans is not clear and serotonin is involved in several functions including cognition. The purpose of this study was to investigate cognitive performance in a group of typical recreational ecstasy users.
METHODS—A comprehensive cognitive test battery was administered to 28 abstinent ecstasy users with concomitant use of cannabis only and to two equally sized matched groups of cannabis users and non-users. The sample consisted of ecstasy users with a typical recreational use pattern and did not include very heavy users.
RESULTS—Ecstasy users were unimpaired in simple tests of attention (alertness). However, they performed worse than one or both control groups in the more complex tests of attention, in memory and learning tasks, and in tasks reflecting aspects of general intelligence. Heavier ecstasy and heavier cannabis use were associated with poorer performance in the group of ecstasy users. By contrast, the cannabis users did not differ significantly in their performance from the non-users.
CONCLUSIONS—The present data raise concern that use of ecstasy possibly in conjunction with cannabis may lead to cognitive decline in otherwise healthy young people. Although the nature of the emerging cognitive disturbance is not yet clear, an impairment of working memory might be the common denominator underlying or contributing to declines of performance in various tasks. The cognitive disturbance is likely to be related to the well recognised neurotoxic potential of ecstasy. The data suggest that even typical recreational doses of ecstasy are sufficient to cause neurotoxicity in humans.



Full Text

The Full Text of this article is available as a PDF (148.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman H. J., Normile H. J. What is the nature of the role of the serotonergic nervous system in learning and memory: prospects for development of an effective treatment strategy for senile dementia. Neurobiol Aging. 1988 Sep-Dec;9(5-6):627–638. doi: 10.1016/s0197-4580(88)80124-6. [DOI] [PubMed] [Google Scholar]
  2. Baddeley A. Working memory. Science. 1992 Jan 31;255(5044):556–559. doi: 10.1126/science.1736359. [DOI] [PubMed] [Google Scholar]
  3. Battaglia G., Yeh S. Y., De Souza E. B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav. 1988 Feb;29(2):269–274. doi: 10.1016/0091-3057(88)90155-4. [DOI] [PubMed] [Google Scholar]
  4. Battaglia G., Yeh S. Y., O'Hearn E., Molliver M. E., Kuhar M. J., De Souza E. B. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther. 1987 Sep;242(3):911–916. [PubMed] [Google Scholar]
  5. Bolla K. I., McCann U. D., Ricaurte G. A. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology. 1998 Dec;51(6):1532–1537. doi: 10.1212/wnl.51.6.1532. [DOI] [PubMed] [Google Scholar]
  6. Coccaro E. F., Siever L. J., Klar H. M., Maurer G., Cochrane K., Cooper T. B., Mohs R. C., Davis K. L. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry. 1989 Jul;46(7):587–599. doi: 10.1001/archpsyc.1989.01810070013002. [DOI] [PubMed] [Google Scholar]
  7. Curran H. V., Travill R. A. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. Addiction. 1997 Jul;92(7):821–831. [PubMed] [Google Scholar]
  8. Fischer C., Hatzidimitriou G., Wlos J., Katz J., Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci. 1995 Aug;15(8):5476–5485. doi: 10.1523/JNEUROSCI.15-08-05476.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gerra G., Zaimovic A., Giucastro G., Maestri D., Monica C., Sartori R., Caccavari R., Delsignore R. Serotonergic function after (+/-)3,4-methylene-dioxymethamphetamine ('Ecstasy') in humans. Int Clin Psychopharmacol. 1998 Jan;13(1):1–9. doi: 10.1097/00004850-199801000-00001. [DOI] [PubMed] [Google Scholar]
  10. Hasbroucq T., Rihet P., Blin O., Possamai C. A. Serotonin and human information processing: fluvoxamine can improve reaction time performance. Neurosci Lett. 1997 Jul 4;229(3):204–208. doi: 10.1016/s0304-3940(97)00451-5. [DOI] [PubMed] [Google Scholar]
  11. Hatzidimitriou G., McCann U. D., Ricaurte G. A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci. 1999 Jun 15;19(12):5096–5107. doi: 10.1523/JNEUROSCI.19-12-05096.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Helmstaedter C., Durwen H. F. VLMT: Verbaler Lern- und Merkfähigkeitstest. Ein praktikables und differenziertes Instrumentarium zur Prüfung der verbalen Gedächtnisleistungen. Schweiz Arch Neurol Psychiatr (1985) 1990;141(1):21–30. [PubMed] [Google Scholar]
  13. Krystal J. H., Price L. H., Opsahl C., Ricaurte G. A., Heninger G. R. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse. 1992;18(3):331–341. doi: 10.3109/00952999209026070. [DOI] [PubMed] [Google Scholar]
  14. Linnoila M., Virkkunen M., Scheinin M., Nuutila A., Rimon R., Goodwin F. K. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci. 1983 Dec 26;33(26):2609–2614. doi: 10.1016/0024-3205(83)90344-2. [DOI] [PubMed] [Google Scholar]
  15. McCann U. D., Mertl M., Eligulashvili V., Ricaurte G. A. Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology (Berl) 1999 Apr;143(4):417–425. doi: 10.1007/s002130050967. [DOI] [PubMed] [Google Scholar]
  16. McCann U. D., Ridenour A., Shaham Y., Ricaurte G. A. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology. 1994 Apr;10(2):129–138. doi: 10.1038/npp.1994.15. [DOI] [PubMed] [Google Scholar]
  17. McCann U. D., Szabo Z., Scheffel U., Dannals R. F., Ricaurte G. A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet. 1998 Oct 31;352(9138):1433–1437. doi: 10.1016/s0140-6736(98)04329-3. [DOI] [PubMed] [Google Scholar]
  18. McEntee W. J., Crook T. H. Serotonin, memory, and the aging brain. Psychopharmacology (Berl) 1991;103(2):143–149. doi: 10.1007/BF02244194. [DOI] [PubMed] [Google Scholar]
  19. Morgan M. J. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology (Berl) 1999 Jan;141(1):30–36. doi: 10.1007/s002130050803. [DOI] [PubMed] [Google Scholar]
  20. Morgan M. J. Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology. 1998 Oct;19(4):252–264. doi: 10.1016/S0893-133X(98)00012-8. [DOI] [PubMed] [Google Scholar]
  21. O'Hearn E., Battaglia G., De Souza E. B., Kuhar M. J., Molliver M. E. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci. 1988 Aug;8(8):2788–2803. doi: 10.1523/JNEUROSCI.08-08-02788.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. O'Keane V., Moloney E., O'Neill H., O'Connor A., Smith C., Dinan T. G. Blunted prolactin responses to d-fenfluramine in sociopathy. Evidence for subsensitivity of central serotonergic function. Br J Psychiatry. 1992 May;160:643–646. doi: 10.1192/bjp.160.5.643. [DOI] [PubMed] [Google Scholar]
  23. Parrott A. C., Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl) 1998 Oct;139(3):261–268. doi: 10.1007/s002130050714. [DOI] [PubMed] [Google Scholar]
  24. Parrott A. C., Lees A., Garnham N. J., Jones M., Wesnes K. Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. J Psychopharmacol. 1998;12(1):79–83. doi: 10.1177/026988119801200110. [DOI] [PubMed] [Google Scholar]
  25. Poulos Constantine X., Parker J.L., Le A.D. Dexfenfluramine and 8-OH-DPAT modulate impulsivity in a delay-of-reward paradigm: implications for a correspondence with alcohol consumption. Behav Pharmacol. 1996 Aug;7(4):395–399. doi: 10.1097/00008877-199608000-00011. [DOI] [PubMed] [Google Scholar]
  26. Ricaurte G. A., Forno L. S., Wilson M. A., DeLanney L. E., Irwin I., Molliver M. E., Langston J. W. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 1988 Jul 1;260(1):51–55. [PubMed] [Google Scholar]
  27. Ricaurte G. A., Martello A. L., Katz J. L., Martello M. B. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther. 1992 May;261(2):616–622. [PubMed] [Google Scholar]
  28. Ricaurte G., Bryan G., Strauss L., Seiden L., Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science. 1985 Sep 6;229(4717):986–988. doi: 10.1126/science.4023719. [DOI] [PubMed] [Google Scholar]
  29. Schmidt C. J. Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. Eur J Pharmacol. 1987 Apr 7;136(1):81–88. doi: 10.1016/0014-2999(87)90782-5. [DOI] [PubMed] [Google Scholar]
  30. Sirviö J., Riekkinen P., Jr, Jäkälä P., Riekkinen P. J. Experimental studies on the role of serotonin in cognition. Prog Neurobiol. 1994 Jul-Aug;43(4-5):363–379. doi: 10.1016/0301-0082(94)90060-4. [DOI] [PubMed] [Google Scholar]
  31. Virkkunen M., Linnoila M. Brain serotonin, type II alcoholism and impulsive violence. J Stud Alcohol Suppl. 1993 Sep;11:163–169. doi: 10.15288/jsas.1993.s11.163. [DOI] [PubMed] [Google Scholar]
  32. Wilson M. A., Ricaurte G. A., Molliver M. E. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience. 1989;28(1):121–137. doi: 10.1016/0306-4522(89)90237-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES